Cun Ku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cun Ku has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chenhang Li
School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen Guangdong China
2 shared publications - Jiyu Xie
School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen Guangdong China
2 shared publications - Manni Wu
School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen Guangdong China
2 shared publications - Yang Zhang
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China
2 shared publications - Ayan Abdrakhmanov
Heart Rhythm Scientific Research Institute, Astana Medical University, Astana, Kazakhstan
1 shared publication - Dong Liang
School of Agriculture and Biotechnology
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Wiley in British Journal of Pharmacology
Inhibition of the NR4A1‐mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity
Background and Purpose: The nuclear receptor NR4A1 is a critical node in transcriptional circuits for metabolic adaptation, yet its role in adipocyte progenitor (AP) fate and proliferation is unclear. We sought to define how NR4A1 governs early adipogenesis and adipose tissue plasticity. Experimental Approach: Doxycycline‐inducible NR4A1‐overexpressing and NR4A1‐deficient 3T3‐L1 models were used to assess lipid accumulation, mitotic clonal expansion (MCE), and cell‐cycle dynamics. Multiomics integration (RNA‐seq and chromatin assays) identified NR4A1 targets. The functionality of two lead candidates, ANLN and CDC20, was tested by genetic knockdown and pharmacological inhibition. Diet‐induced obese mice received the NR4A1 antagonist C‐DIM8 alone or combined with the PPARγ agonist rosiglitazone to evaluate adipose expansion and metabolic outcomes. Key Results: NR4A1 exerted a stage‐specific inhibitory effect during early differentiation, reducing expression of canonical adipogenic markers and lipid accumulation. Integrative transcriptomic and chromatin analyses identified Anln and Cdc20 as direct NR4A1 targets essential for MCE. Depletion of either gene phenocopied NR4A1 overexpression, inducing G2/M arrest and blunting of adipogenesis. Pharmacological CDC20 inhibition with Apcin suppressed preadipocyte proliferation and differentiation in a dose‐dependent manner. Importantly, in a diet‐induced obese mouse model, combined treatment with the NR4A1 antagonist C‐DIM8 and the PPARγ agonist rosiglitazone promoted AP proliferation, hyperplastic adipose tissue expansion, and improved glucose tolerance. Conclusions and Implications: NR4A1 functions as a transcriptional gatekeeper of adipogenic initiation by restraining the Anln / Cdc20 cell‐cycle program. Pharmacological modulation of the NR4A1–cell‐cycle axis, particularly alongside PPARγ activation, may offer a strategy to augment adipose tissue plasticity and metabolic resilience in obesity.
- 2 October 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessInhibition of the NR4A1‐mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity
Background and Purpose: The nuclear receptor NR4A1 is a critical node in transcriptional circuits for metabolic adaptation, yet its role in adipocyte progenitor (AP) fate and proliferation is unclear. We sought to define how NR4A1 governs early adipogenesis and adipose tissue plasticity. Experimental Approach: Doxycycline‐inducible NR4A1‐overexpressing and NR4A1‐deficient 3T3‐L1 models were used to assess lipid accumulation, mitotic clonal expansion (MCE), and cell‐cycle dynamics. Multiomics integration (RNA‐seq and chromatin assays) identified NR4A1 targets. The functionality of two lead candidates, ANLN and CDC20, was tested by genetic knockdown and pharmacological inhibition. Diet‐induced obese mice received the NR4A1 antagonist C‐DIM8 alone or combined with the PPARγ agonist rosiglitazone to evaluate adipose expansion and metabolic outcomes. Key Results: NR4A1 exerted a stage‐specific inhibitory effect during early differentiation, reducing expression of canonical adipogenic markers and lipid accumulation. Integrative transcriptomic and chromatin analyses identified Anln and Cdc20 as direct NR4A1 targets essential for MCE. Depletion of either gene phenocopied NR4A1 overexpression, inducing G2/M arrest and blunting of adipogenesis. Pharmacological CDC20 inhibition with Apcin suppressed preadipocyte proliferation and differentiation in a dose‐dependent manner. Importantly, in a diet‐induced obese mouse model, combined treatment with the NR4A1 antagonist C‐DIM8 and the PPARγ agonist rosiglitazone promoted AP proliferation, hyperplastic adipose tissue expansion, and improved glucose tolerance. Conclusions and Implications: NR4A1 functions as a transcriptional gatekeeper of adipogenic initiation by restraining the Anln / Cdc20 cell‐cycle program. Pharmacological modulation of the NR4A1–cell‐cycle axis, particularly alongside PPARγ activation, may offer a strategy to augment adipose tissue plasticity and metabolic resilience in obesity.
- Open Access
- 16 June 2026
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 31 (3)
Genistein Restores Nitric Oxide Bioavailability and Attenuates Oxidative Stress in Angiotensin II-Induced Hypertensive Mice
Genistein is a dietary isoflavone that is abundant in soy products and has been suggested to exert cardiovascular protective effects; however, its role in hypertension remains incompletely defined. Here, we investigated whether genistein ameliorates angiotensin II (Ang II)-induced hypertension and endothelial dysfunction using complementary in vivo, ex vivo, and in vitro models. The oral administration of genistein substantially attenuated Ang II-induced elevations in systolic and diastolic blood pressure in mice without affecting body weight. Histological analyses revealed that genistein alleviated aortic wall thickening and smooth muscle hypertrophy, whereas vascular reactivity assays demonstrated improved endothelium-dependent relaxation while preserving the endothelium-independent responses. In isolated murine aortic rings, genistein reversed Ang II-induced hypercontractility and restored acetylcholine-mediated vasodilation. Furthermore, in human umbilical vein endothelial cells, genistein suppressed the Ang II-induced overproduction of reactive oxygen species (ROS) and restored nitric oxide (NO) bioavailability. Mechanistically, genistein improved endothelial redox-NO coupling, accompanied by transcriptional remodeling of the redox/NO axis [e.g., suppression of nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and nitric oxide synthase 2 (NOS2) and restoration of nitric oxide synthase 3 (NOS3)], which is consistent with reduced ROS and enhanced NO bioavailability. Collectively, our findings identify genistein as a potent endothelial-protective agent that ameliorates Ang II-induced hypertension, highlighting its therapeutic potential in cardiovascular disease driven by vascular dysfunction.
- 16 June 2026
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 31 (3)
Open AccessGenistein Restores Nitric Oxide Bioavailability and Attenuates Oxidative Stress in Angiotensin II-Induced Hypertensive Mice
Genistein is a dietary isoflavone that is abundant in soy products and has been suggested to exert cardiovascular protective effects; however, its role in hypertension remains incompletely defined. Here, we investigated whether genistein ameliorates angiotensin II (Ang II)-induced hypertension and endothelial dysfunction using complementary in vivo, ex vivo, and in vitro models. The oral administration of genistein substantially attenuated Ang II-induced elevations in systolic and diastolic blood pressure in mice without affecting body weight. Histological analyses revealed that genistein alleviated aortic wall thickening and smooth muscle hypertrophy, whereas vascular reactivity assays demonstrated improved endothelium-dependent relaxation while preserving the endothelium-independent responses. In isolated murine aortic rings, genistein reversed Ang II-induced hypercontractility and restored acetylcholine-mediated vasodilation. Furthermore, in human umbilical vein endothelial cells, genistein suppressed the Ang II-induced overproduction of reactive oxygen species (ROS) and restored nitric oxide (NO) bioavailability. Mechanistically, genistein improved endothelial redox-NO coupling, accompanied by transcriptional remodeling of the redox/NO axis [e.g., suppression of nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and nitric oxide synthase 2 (NOS2) and restoration of nitric oxide synthase 3 (NOS3)], which is consistent with reduced ROS and enhanced NO bioavailability. Collectively, our findings identify genistein as a potent endothelial-protective agent that ameliorates Ang II-induced hypertension, highlighting its therapeutic potential in cardiovascular disease driven by vascular dysfunction.